EANS-Adhoc: NiteWatch Home Sleep Testing service receives Joint Commission accreditation as an "Ambulatory Health Care Program"

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

23.11.2009

Neuhausen am Rheinfall / Switzerland, November 23, 2009 - LifeWatch AG (SIX
Swiss Exchange: LIFE), the leading provider of wireless cardiac and other
medical monitoring services in the U.S., announced today that its "NiteWatch"
home sleep testing service has been accredited with the Joint Commission for
"Ambulatory Health Care Programs", and is one of only a few independent
diagnostic testing facilities (IDTFs) which have received this Gold Seal of
Approval.

"Joint Commission certification endorses LifeWatch as an organization committed
to clinical excellence and quality" stated Marikay Menard, Vice President of
Clinical Strategy and Regulatory Affairs of LifeWatch Services, Inc. "The
expansion of this certification to our NiteWatch Home Sleep Testing service
confirms this commitment to quality as we expand our medical service offering
to home sleep testing in the first quarter of 2010.

The Joint Commission on Accreditation of Healthcare Organizations evaluates and
accredits nearly 17,000 health care organizations and programs in the United
States. As an independent, not-for-profit organization, the Joint Commission is
the nation´s predominant standards-setting and accrediting body in health care.

"This additional accreditation further demonstrates LifeWatch´s commitment to
provide patients with the highest quality clinical services in the industry,"
stated Dr. Yacov Geva, Chairman and Chief Executive Officer of LifeWatch AG.

NiteWatch provides Home Sleep Testing for diagnosing Obstructive Sleep Apnea
(OSA), a widely undiagnosed medical condition that is highly correlated with
other chronic diseases. Thirty eight million Americans are affected by OSA, of
which fifteen million are undiagnosed. The U.S. market for OSA is currently
estimated at USD 1.5 billion, out of which an estimated one million tests are
conducted annually. This market is projected to grow between 20-50% in the next
five years, with home sleep testing capturing approximately 20% of the total
market. LifeWatch, as the first Cardiac IDTF to enter into home sleep testing
services, will leverage its medical monitoring expertise into a competitive
advantage, and diversify LifeWatch´s service offering. LifeWatch is fully on
track with its planned roll out of the NiteWatch service and has expanded its
beta launch to 12 clients and is now approaching 50 patients. The Company has
already signed 166 commercial managed care contracts covering 90 million lives
for its new NiteWatch service and will continue to broaden coverage with
additional contracts.

About LifeWatch AG

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss
Exchange (LIFE), Switzerland, is the leading healthcare technology and solution
company, specializing in advanced telehealth systems and wireless remote
patient monitoring services. LifeWatch services treat high-risk and chronically
ill patients, health conscious consumers and wellness programs. LifeWatch has
subsidiaries in the United States, the Netherlands, Japan, the United Kingdom,
Switzerland and Israel. LifeWatch AG is the parent company of LifeWatch
Services Inc., a leading US-based cardiac monitoring service provider, and
manufacturer of telecardiology products. LifeWatch is also introducing a new
program for Home Sleet Testing of Obstructive Sleep Apnea (OSA) patients under
the brand name NiteWatch. For additional information, please visit
www.lifewatch.com and www.nitewatchservices.com

Sign-up for customized e-mail alerts and documentation requests is available at
http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All statements other
than statements of historical facts contained in this press release, including
statements regarding future results of operations and financial position,
business strategy and plans and objectives for future operations, are
forward-looking statements. The words "believe," "may," "will," "estimate,"
"continue," "anticipate," "intend," "expect" and similar expressions are
intended to identify forward-looking statements. LifeWatch AG has based these
forward looking statements largely on current expectations and projections
about future events and financial trends that it believes may affect the
financial condition, results of operations, business strategy, short term and
long term business operations and objectives, and financial needs. These
forward-looking statements are subject to a number of risks, uncertainties and
assumptions. In light of these risks, uncertainties and assumptions, the
forward-looking events and circumstances described may not occur and actual
results could differ materially and adversely from those anticipated or implied
in the forward-looking statements. All forward-looking statements are based
only on data available to LifeWatch AG at the time of the issue of this press
release. LifeWatch AG does not undertake any obligation to update any forward-
looking statements contained in this press release as a result of new
information, future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A
GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT
CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES
FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY
SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN
ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD
OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION
UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE
UNITED STATES SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN
THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED
FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS
OF THE ISSUER.

Further inquiry note:
Kobi Ben Efraim, Chief Financial Officer, LifeWatch AG:
Tel +41 52 632 00 50 | Fax +41 52 632 00 51 | E-mail kobibe@lifewatch.com

Sensus Investor & Public Relations GmbH, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | E-mail lifewatch@sensus.ch
end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer:   LifeWatch AG
          Rundbuckstrasse 6
          CH-8212 Neuhausen am Rheinfall
phone:    +41 52 632 00 50
FAX:      +41 52 632 00 51
mail:     users@lifewatch.com
WWW:      www.lifewatch.com
sector:   Healthcare Providers
ISIN:     CH0012815459
indexes:  SPI, SPIEX

stockmarkets: Open Market / XETRA: Frankfurt, Hauptsegment: SIX Swiss Exchange, free
trade: Berlin
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print